ET-01 clinical trials
Also written ET-01.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How each study uses ET-01 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ET-01
- 3
Studies by the year they started
3 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 2 |
Who runs them
Industry 2 · Other 1
EdiGene (GuangZhou) Inc. (2) · Institute of Hematology & Blood Diseases Hospital, China (1)
Studies
Open first, then newest update. How each study uses ET-01 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-ThalassaemiaCompletedNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT04390971Written as ET-01
- A Study to Evaluate the Safety and Efficacy of ET-01 Transplantation in Subjects with Transfusion Dependent Β-Thalassaemia.TerminatedNot applicableEdiGene (GuangZhou) Inc.NCT05752123Written as ET-01
- A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-ThalassaemiaTerminatedPhase 1EdiGene (GuangZhou) Inc.NCT04925206Written as ET-01